Prenatal acetaminophen exposure and the developing ovary: Time, dose, and course consequences for fetal mice
Food and Chemical Toxicology · 2024
DOI: 10.1016/j.fct.2024.114679 ↗Kurz gefasst
Fachartikel in der Zeitschrift Food and Chemical Toxicology, 2024. Verfasst von Tiancheng Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. Hauptthemen laut MEDLINE: Acetaminophen, Ovary. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Acetaminophen is an emerging endocrine disrupting chemical and has been detected in various natural matrices. Numerous studies have documented developmental toxicity associated with prenatal acetaminophen exposure (PAcE). In this study, we established a PAcE Kunming mouse model at different time (middle pregnancy and third trimester), doses (low, middle, high) and courses (single or multi-) to systematically investigate their effects on fetal ovarian development. The findings indicated PAcE affected ovarian development, reduced fetal ovarian oocyte number and inhibited cell proliferation. A reduction in mRNA expression was observed for genes associated with oocyte markers (NOBOX and Figlα), follicular development markers (BMP15 and GDF9), and pre-granulosa cell steroid synthase (SF1 and StAR). Notably, exposure in middle pregnancy, high dose, multi-course resulted in the most pronounced inhibition of oocyte development; exposure in third trimester, high dose and multi-course led to the most pronounced inhibition of follicular development; and in third trimester, low dose and single course, the inhibition of pre-granulosa cell function was most pronounced. Mechanistic investigations revealed that PAcE had the most pronounced suppression of the ovarian Notch signaling pathway. Overall, PAcE caused fetal ovarian multicellular toxicity and inhibited follicular development with time, dose and course differences.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
- Department of Otorhinolaryngology and HN Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China; Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, 430071, China.
- Department of Pharmacology, School of Basic Medical Sciences, Wuhan University, Wuhan, 430071, China; Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, 430071, China.
- Department of Obstetrics, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China; Department of Pharmacology, School of Basic Medical Sciences, Wuhan University, Wuhan, 430071, China; Hubei Provincial Key Laborator…
- Department of Obstetrics, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China; Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan, 430071, China; Clinical Research Center for Prenatal D…
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Wu, T., Huang, J., Li, Y., Guo, Y., Wang, H., & Zhang, Y. (2024). Prenatal acetaminophen exposure and the developing ovary: Time, dose, and course consequences for fetal mice. Food and Chemical Toxicology. https://doi.org/10.1016/j.fct.2024.114679
Vancouver
Wu T, Huang J, Li Y, Guo Y, Wang H, Zhang Y. Prenatal acetaminophen exposure and the developing ovary: Time, dose, and course consequences for fetal mice. Food and Chemical Toxicology. 2024. doi:10.1016/j.fct.2024.114679
BibTeX
@article{Wu2024,
author = {Wu, Tiancheng and Huang, Jing and Li, Yating and Guo, Yu and Wang, Hui and Zhang, Yuanzhen},
title = {Prenatal acetaminophen exposure and the developing ovary: Time, dose, and course consequences for fetal mice},
journal = {Food and Chemical Toxicology},
year = {2024},
doi = {10.1016/j.fct.2024.114679}
}
EUVIMED